Register through Sept. 17 to receive the lowest rates for Advancing Gene + Cell Therapies for Cancer.
In Q3, a CAR T-cell therapy was approved for multiple myeloma in China and an mRNA vaccine was approved for COVID-19 in Japan.
The third quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
An anti-BCMA-targeting CAR T-cell therapy, Fucaso, was approved for multiple myeloma in China
An mRNA vaccine, Daichirona, was approved for COVID-19 in Japan
For the first time in more than a year, COVID-19 complications is no longer in the top three specified indications for non-genetically modified cell therapy development
Download the full report
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico